glycopyrrolate formoterol Bevespi Aerosphere
Selected indexed studies
- Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. (Am J Respir Crit Care Med, 2021) [PMID:33252985]
- Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD. (Med Lett Drugs Ther, 2016) [PMID:27701364]
- Pharmaceutical Approval Update. (P T, 2016) [PMID:27630521]
_Worker-drafted node — pending editorial review._
Connections
glycopyrrolate formoterol Bevespi Aerosphere is a side effect of
Sources
- Glycopyrronium/Formoterol: A Review in COPD. (2019) pubmed
- Budesonide/Glycopyrronium/Formoterol: A Review in COPD. (2021) pubmed
- Glycopyrrolate and formoterol fumarate for the treatment of COPD. (2021) pubmed
- Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. (2021) pubmed
- Drugs for COPD. (2020) pubmed
- Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. (2026) pubmed
- Drugs for COPD. (2024) pubmed
- Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study. (2025) pubmed
- Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD. (2016) pubmed
- Pharmaceutical Approval Update. (2016) pubmed